Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market.

Bausch + Lomb Corporation (NYSE ... most notably, Lumify and PreserVision, our high-margin performers that bolster the top and bottom line. Now let me turn it over to Sam. Sam Eldessouky: Thank ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

When he was twenty years old in 1849, he emigrated to the United States. Lomb worked as a carpenter before he joined John Jacob Bausch, the owner of a retail optical shop in Rochester. Lomb invested ...

His friend Henry Lomb invested his savings in Bausch's shop and in 1855 became his partner. Even with the loan, the business floundered until Bausch stumbled upon a piece of vulcanized rubber on a ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the ...

Raising full-year 2024 constant currency revenue growth guidance from 12-14% to 13-15%. Full-year revenue range of $4.600 – $4.700 billion. Full-year Adjusted EBITDA (non-GAAP) range of $840 ...

GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP) 1 of $180 Million Revenue Grew 18% as Reported and 20% on a Constant Currency 1 Basis Compared to ...

Bausch + Lomb (NYSE:BLCO) said a study for its new nutritional supplement for dry eyes met its primary endpoints of change in tear production and participant reports of dry eye symptoms.

It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products.